COVID-19 and Pulmonary Thrombosis-An Unresolved Clinical Puzzle: A Single-Center Cohort Study.
Loris MočibobFrano ŠušakMaja ŠitumKlaudija ViškovićNeven PapićAdriana VincePublished in: Journal of clinical medicine (2022)
Pulmonary thrombosis (PT) is a frequent complication of COVID-19. However, the risk factors, predictive scores, and precise diagnostic guidelines on indications for CT pulmonary angiography (CTPA) are still lacking. This study aimed to analyze the clinical and laboratory characteristics associated with PT in patients with COVID-19. We conducted a cohort study of consecutively hospitalized adult patients with COVID-19 who underwent CTPA at the University Hospital for Infectious Diseases in Zagreb, Croatia between 1 April and 31 December 2021. Of 2078 hospitalized patients, 575 (27.6%) underwent CTPA. PT was diagnosed in 178 (30.9%) patients (69.6% males, median age of 61, IQR 50-69 years). The PT group had a higher CRP, LDH, D-dimer, platelets, and CHOD score. PT was more frequent in patients requiring ≥15 L O 2 /min (25.0% vs. 39.7%). In multivariable analysis, only D-dimer ≥ 1.0 mg/L (OR 1.78, 95%CI 1.12-2.75) and O 2 ≥ 15 L (OR 1.89, 95%CI 1.26-2.84) were associated with PT. PT was not associated with in-hospital mortality. In conclusion, our data confirmed a high incidence of PT in hospitalized patients with COVID-19, however, no correlation with traditional risk factors and mortality was found. CTPA should be performed in patients requiring high-flow supplemental oxygen or those with increased D-dimer levels.
Keyphrases
- risk factors
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- coronavirus disease
- pulmonary hypertension
- sars cov
- prognostic factors
- type diabetes
- peritoneal dialysis
- pulmonary embolism
- magnetic resonance imaging
- young adults
- infectious diseases
- coronary artery disease
- cardiovascular events
- magnetic resonance
- patient reported outcomes
- positron emission tomography
- image quality